Cannabis Law and Access in Iceland

Why cannabis law in Iceland is stricter than most people expect

Forty-three countries now have some form of regulated cannabis access. Iceland is not one of them. That surprises a lot of readers, partly because Iceland sits geographically and culturally close to Nordic neighbours who have at least opened limited medical pathways, and partly because the country has a reputation for pragmatism on social policy. The reality is more conservative than the reputation suggests.

Cannabis, in virtually all its forms, remains a controlled substance under Icelandic law, and the framework has changed less in the past decade than almost anywhere else in Western Europe. It is worth understanding why, and what the actual legal architecture looks like. For readers who like to compare, our articles on cannabis law in Sweden and cannabis law in Denmark show how neighbouring systems differ.

The legislative foundation: Act on Narcotic Substances

Iceland's primary instrument is the Act on Narcotic Substances No. 65/1974, along with subsequent regulations issued by the Ministry of Health. Cannabis is classified under Schedule I-equivalent provisions, meaning it is treated as having no recognised licit use in domestic law outside of very narrow research or import-authorised contexts. Possession, sale, cultivation and supply are all criminal offences.

Penalties scale with quantity and intent. Simple possession of a small amount can still attract fines and criminal record consequences. Iceland has not moved toward the decriminalisation-lite model that, say, Portugal adopted in 2001 or that several other European states have since experimented with. There is no administrative infringement pathway the way there is in, for example, the ACT here in Australia (where personal possession of small amounts was decriminalised in 2020 under the Drugs of Dependence (Personal Use) Amendment Act 2022). In Iceland, a possession offence is still a possession offence.

When reading about this topic, it pays to go back to primary material such as the EMCDDA's country drug reports, because the secondary sources online are genuinely inconsistent. A few cannabis-adjacent sites confidently describe an Icelandic "medical programme." There isn't one in any meaningful structured sense. A common mistake is to treat a single web page as if it were the statute; the Act and its regulations are the thing to check, and a summary is only ever a pointer to them.

Is there any medical access pathway?

This is where it gets nuanced. Iceland is a member of the European Economic Area (EEA) but not the European Union. That distinction matters for regulatory alignment. EU member states that have established medical cannabis frameworks, Germany being the most prominent example following its Cannabis Act reforms (see our piece on cannabis law in Germany), operate under structures that Iceland is not automatically bound to replicate or recognise.

The Icelandic Medicines Agency (Lyfjastofnun) can authorise importation of specific medicinal products on a named-patient or compassionate-use basis. In practice, this means an Icelandic physician can, in principle, apply to import a cannabis-derived medicine that holds regulatory approval in another jurisdiction, for instance, a product based on cannabidiol (CBD) that has received marketing authorisation in Europe. The process is not a standing programme with defined approval criteria publicly available in the way Australia's Special Access Scheme Scheme B pathway is documented on the TGA website. It is case-by-case, slow, and from all available reporting, extremely rarely used.

The terminology matters here. "Named-patient" means an application tied to one identified person rather than a general listing, and "compassionate use" describes an exception route rather than a routine one. Neither amounts to a programme that patients can expect to enter as of right.

There is no Authorised Prescriber-equivalent scheme, no cultivated domestic supply, and no licensed dispensary infrastructure. The comparison to frameworks like those covered in our Special Access Scheme overview is instructive, and our explainer on understanding the Special Access Scheme sets out how a documented route looks in practice: Iceland simply has no analogous architecture.

CBD specifically: a complicated picture

Here is where Iceland diverges somewhat from its own general prohibitionist position, and where the law gets genuinely unclear even for people trying to apply it carefully.

CBD products derived from hemp, meaning Cannabis sativa varieties with very low THC concentrations, have entered the Icelandic market as food supplements and cosmetics, in a pattern familiar across Europe. Icelandic authorities have not always moved quickly to remove these products, and enforcement has been inconsistent. However, the legal status of CBD isolate and full-spectrum hemp extracts as supplements is not formally settled under Icelandic law. Lyfjastofnun has indicated that CBD, when it is intended to affect physiological function, likely falls under medicinal product regulation rather than food supplement regulation, which circles it back to the controlled substance framework.

The EU Novel Food Regulation, which classifies CBD extracts as novel foods requiring pre-market authorisation, applies across the EEA including Iceland. Icelandic food authorities have, in principle, aligned with this. What this means in practice is that CBD hemp products circulating in Icelandic shops occupy a contested grey zone, not a cleared licit space. The short version is: don't assume availability equals legality.

Why does the product category matter so much? Because the same molecule can be regulated as a food, a cosmetic or a medicine depending on its intended purpose and how it is presented. Once a product is framed as affecting physiological function, it moves toward medicines law. Shelf presence says nothing about whether that classification question has been resolved.

Hemp cultivation and industrial uses

Iceland does permit cultivation of hemp varieties with THC below the EU threshold (0.2% by dry weight under the current EU Common Agricultural Policy framework, to which Iceland is not bound by treaty but which it references in practice). However, the cultivation sector is tiny. Iceland's climate, with short growing seasons, volcanic soil variability and limited agricultural land, makes large-scale hemp cultivation economically marginal at best. There is no established domestic hemp industry comparable to those in France, the Netherlands or even Lithuania.

The hemp that does get grown is primarily for fibre or seed oil, not for CBD extraction. Honestly, the economic conditions for a domestic cannabinoid supply chain just aren't there yet.

The distinction between industrial hemp and drug-type cannabis is one of chemistry and legal definition, not of botany alone. A THC threshold is the line regulators use, which is why the permitted variety, rather than the plant species, is what the rules actually describe.

Recreational cannabis: no reform on the horizon

Iceland has not introduced any recreational legalisation legislation, and as of mid-2025 there are no active parliamentary bills moving toward it. Public polling in Iceland on cannabis legalisation is more mixed than in comparable small Nordic or Atlantic nations, and the political coalition currently governing has shown no appetite for it.

This contrasts markedly with Germany's Cannabisgesetz (CanG), which from April 2024 allowed adults to possess limited amounts and form cannabis social clubs, or with Malta's 2021 reforms that created a personal possession and home grow framework. Iceland is watching those developments, but watching is all it is doing for now.

I'd argue this conservatism is partly a structural artefact of Iceland's small population and the outsized political weight of its law enforcement and health professional lobby groups, both of which have historically framed cannabis primarily as a public health concern rather than a regulatory one. Whether that framing holds as European reform accelerates is a genuine open question.

What Australians researching this need to understand

Readers here sometimes look at international frameworks to benchmark where Australia sits, which is a fair exercise. The quick comparison: Australia's framework under the Narcotic Drugs Act 1967 and the TGA's scheduling instruments is more permissive than Iceland's in one significant respect; there is a structured medical access pathway. Cannabis-derived medicines sit under Schedule 8 (Controlled Drug) or Schedule 4 (Prescription Only) depending on the product and THC concentration, and access routes through the TGA's Special Access Scheme and Authorised Prescriber framework are publicly documented and actively used, tens of thousands of approvals have been granted since 2016.

Iceland has none of that infrastructure. For an Australian thinking about the global landscape, Iceland sits closer to Japan or South Korea in its overall restrictiveness than to Germany or Australia.

One note for completeness: nothing in Iceland's framework affects what Australians can access domestically. Australian law governs what can be prescribed, dispensed and possessed in Australia regardless of what any other country does. The TGA and the Poisons Standard are the operative instruments for any Australians seeking access to cannabis-derived medicines, not foreign frameworks, however interesting those frameworks may be to study. The Therapeutic Goods Administration publishes the official position.

What strikes me, reading the actual text of the law, is how rarely the "progressive Nordic country" assumption survives contact with it. Iceland is a good case in point.

The science of how cannabinoids interact with the endocannabinoid system is evolving quickly. Regulatory frameworks move much more slowly, and Iceland's is, for now, staying put.

Sources

• Iceland Drug Report 2023, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Lyfjastofnun; Icelandic Medicines Agency (official portal)
• Single Convention on Narcotic Substances 1961, United Nations Office on Drugs and Crime
• Accessing medicinal cannabis products, Therapeutic Goods Administration (TGA)

Marcus Hale, Regulatory researcher; TGA & access law